Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials
Cancer Treatment Reviews · 2026-11 · 150 · 103213
DOI: 10.1016/j.ctrv.2026.103213 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-11. Verfasst von Ana-Maria Dudău und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gustave Roussy, Villejuif, France; Titu Maiorescu University, Bucharest, Romania. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Selective Estrogen Receptor Modulators. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Gustave Roussy, Villejuif, France; Titu Maiorescu University, Bucharest, Romania.
- Department of Medical Oncology, Gustave Roussy, Villejuif, France.
- Department of Medical Oncology, Comprehensive Cancer Centre F. Baclesse, UNICANCER, Caen, France.
- Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France.
- Institut Godinot, Reims, France.
- Early Drug Development for Innovative Therapies, European Institute of Oncology IRCSS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy.
Zitieren
APA
Dudău, A. M., Zeghondy, J., Emile, G., Simon, C., Lottin, M., Marra, A., Aftimos, P., Boussios, S., Xu-Vuillard, A., Lion, O., Serhal, C., Ribeiro, J. M., Pistilli, B., Michiels, S., & Rassy, E. (2026). Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials. Cancer Treatment Reviews, 150, 103213. https://doi.org/10.1016/j.ctrv.2026.103213
Vancouver
Dudău AM, Zeghondy J, Emile G, Simon C, Lottin M, Marra A, et al. Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials. Cancer Treatment Reviews. 2026;150:103213. doi:10.1016/j.ctrv.2026.103213
BibTeX
@article{Dudu2026,
author = {Dudău, Ana-Maria and Zeghondy, Jean and Emile, George and Simon, Camille and Lottin, Marine and Marra, Antonio and Aftimos, Philippe and Boussios, Stergios and Xu-Vuillard, Alexandre and Lion, Ophélie and Serhal, Chloe and Ribeiro, Joana M and Pistilli, Barbara and Michiels, Stefan and Rassy, Elie},
title = {Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials},
journal = {Cancer Treatment Reviews},
year = {2026},
volume = {150},
pages = {103213},
doi = {10.1016/j.ctrv.2026.103213}
}
EUVIMED